NuCana PLC (NCNA) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $2.19
• Market Cap: $4.08M
• P/E Ratio: 0.01
• EPS: $404.87
• 52-Week High: $268.00
• 52-Week Low: $2.00

Market Sentiment

NuCana PLC currently has a Bearish sentiment score of -0.33.

About NuCana PLC

NuCana PLC is a clinical-stage biopharmaceutical firm headquartered in Edinburgh, UK, dedicated to developing transformative cancer therapies through its proprietary ProTide technology platform. This innovative approach is designed to improve the efficacy and safety of conventional chemotherapy agents, addressing significant unmet needs in oncology. The company’s lead candidates are currently undergoing clinical trials for various malignancies, including colorectal and pancreatic cancer. With...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for NuCana PLC and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does NCNA pay dividends?

NuCana PLC (NCNA) does not currently pay a regular dividend.

What is NCNA's P/E ratio?

NuCana PLC has a price-to-earnings (P/E) ratio of 0.01.

What is NCNA's market cap?

NuCana PLC (NCNA) has a market capitalization of $4.08M with a current stock price of $2.19.